4 papers in the library · 812 citations · publishing 2001-2004
Neuropsychobiology 2004 Nikolas Coupland, Tai-Jui Chen, Terence O'Donnell et al. 1 citation
event-related potentials 1, 167, 182 -evoked potentials 128, 288, 292 Autistic disorder 157 Averaged diffusion coefficient 119 'Ayahuasca' 89 Bipolar disorder 206, 239 ß-Carboline alkaloids/N,N-dimethyltryptamine ('ayahuasca') 89 Catechol-O-methyltransferase gene 153 Caudate nucleus 296 Cerebellar peduncle 119
Journal of Pharmacology and Experimental Therapeutics June 18, 2003 Jordi Riba, Marta Valle, Gloria Urbano et al. 383 citations
The effects of the South American psychotropic beverage ayahuasca on subjective and cardiovascular variables and urine monoamine metabolite excretion were evaluated, together with the drug's pharmacokinetic profile, in a double-blind placebo-controlled clinical trial. This pharmacologically complex tea, commonly obtained from Banisteriopsis caapi and Psychotria viridis, combines...
British Journal of Clinical Pharmacology June 1, 2002 Jordi Riba, P. Anderer, Adelaida Morte et al. 126 citations
Aims Ayahuasca is a traditional South American psychoactive beverage used in Amazonian shamanism, and in the religious ceremonies of Brazilian‐based syncretic religious groups with followers in the US and several European countries. This tea contains measurable amounts of the psychotropic indole N , N ‐dimethyltryptamine (DMT), and β‐carboline alkaloids with MAO‐inhibiting properties. In a...
Psychopharmacology February 22, 2001 Jordi Riba, Antoni Rodrı́guez-fornells, Gloria Urbano et al. 302 citations
RationaleAyahuasca is a South American psychoactive beverage that contains the naturally occurring psychedelic agent N,N-dimethyltryptamine (DMT). This "tea" has been used for centuries in religious and medicinal contexts in the rain forest areas of South America and is presently gaining the attention of psychedelic users in North America and Europe.ObjectivesIn the present study, the...